No Data
Retail Investors Are Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Biggest Owners and Were Hit After Market Cap Dropped CN¥813m
Jiangsu Nhwa Pharmaceutical (002262.SZ): Independent Director Academician Wang Guangji resigns.
On December 30, Gelonghui reported that Jiangsu Nhwa Pharmaceutical (002262.SZ) announced that the Board of Directors recently received a resignation letter from independent director Academician Wang Guangji, who, due to the need to comply with the regulations for part-time management stipulated in the 'Management Measures for Academicians of the Chinese Academy of Engineering,' applied to resign from his positions as independent director and member of the Board of Directors' Global Strategy Committee. After his resignation, Academician Wang Guangji will no longer hold any position in the company.
Jiangsu Nhwa Pharmaceutical Secures Approval for Mivacurium Chloride Injection
Is Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Stock's Recent Performance A Reflection Of Its Financial Health?
Nhwa Pharma's Opioids Gets China Drug Trial Approval
Jiangsu NHWA Pharmaceutical (002262.SZ): Type 1 chemical drug NH160030 tablets approved for clinical trials.
Gelonghui November 12th | Jiangsu NHWA Pharmaceutical (002262.SZ) announced that the company recently received the approval and issuance of a Type 1 chemical drug NH160030 tablet with 4 specifications by the National Medical Products Administration (hereinafter referred to as the "NMPA"), and will conduct clinical trials in the near future. NH160030 is an orally biased μ-opioid receptor agonist, a new generation of opioid analgesics. Preclinical trial results show that compared to commonly used opioid analgesics such as morphine and hydrocodone, it has superior efficacy and fewer side effects. NH160030 is derived from internal research.
Little Excitement Around Jiangsu Nhwa Pharmaceutical Co., LTD's (SZSE:002262) Earnings
No Data
